In male mice with acute liver failure, intraperitoneal INCB 3284 dimesylate pretreatment before AOM significantly delayed neurological decline, increased time to coma, and reduced serum ALT levels compared with AOM-treated mice. In male Sprague–Dawley rats in the PHH group, intraperitoneal INCB 3284 administered before and after IVH produced a pronounced reduction in ventriculomegaly compared with vehicle-treated rats. In male Sprague-Dawley rats subjected to hemorrhagic shock, a single dose of INCB 3284 administered through the left femoral artery transiently reduced fluid resuscitation requirements compared with vehicle-treated animals. [1,2,3]
Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.
Delayed Neurological Decline in Acute Liver Failure
Animal study · male C57Bl/6 mice; Acute liver failure; n = 4 [1]
In male mice with acute liver failure, intraperitoneal INCB pretreatment before AOM significantly delayed neurological decline and increased time to coma compared with AOM-treated mice.
Conditions shared by the study groups
- Route
- ip
- Treatment course
- for 3 days prior to injection of AOM
- INCB 3284 dimesylate 1 mg/kg/day
- Model: male C57Bl/6 mice; Acute liver failure; n = 4
- Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations
Compound reported in the paper: INCB 3284 dimesylate; Compound label in the paper: INCB 3284
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Methods > Materials (S5); Methods > Mouse model of hepatic encephalopathy (S7, S9, S10, S12); Results > Inhibition of CCR2 or CCR4 is protective from AOM-induced neurological decline (S70); Figure 3 legend (S97, S103)
Time to coma, in hours: Time to coma, in hours; comparator: AOM-treated mice — Methods > Mouse model of hepatic encephalopathy (S10); Results > Inhibition of CCR2 or CCR4 is protective from AOM-induced neurological decline (S70); Figure 3 legend (S97, S103)
INCB 3284 dimesylate 1 mg/kg/day · Methods > Mouse model of hepatic encephalopathy (S10); Results > Inhibition of CCR2 or CCR4 is protective from AOM-induced neurological decline (S70); Figure 3 legend (S103)
Reduced Ventriculomegaly in PHH Rats
Animal study · Male Sprague‒Dawley rats; PHH group; n = 3 animals per condition [2]
In male Sprague–Dawley rats in the PHH group, intraperitoneal INCB 3284 administered before and after IVH produced a pronounced reduction in ventriculomegaly compared with vehicle-treated rats.
Conditions shared by the study groups
- Route
- intraperitoneal injections
- Treatment course
- every 12 h starting 12 h before IVH and continuing until 36 h after IVH
- Vehicle
- 10% DMSO in corn oil
- INCB 3284 1 mg/kg
- Model: Male Sprague‒Dawley rats; PHH group; n = 3 animals per condition
Methods and source locations
Compound reported in the paper: INCB 3284
The paper names INCB 3284 without stating the salt or form; not verified as the dimesylate form supplied as A11104. No dose conversion or lot validation.
Materials and methods > Animals (S1); Materials and methods > Posthemorrhagic hydrocephalus (PHH) models (S38); Materials and methods > Drug administration (S63, S64); Results > ChP CCL2 or CCR2 deficiencies effectively mitigate macrophage infiltration, reduce ChP inflammation, and ameliorate hydrocephalus in vivo (S218); Figure 7 legend (S316, S318)
Lateral ventricles volume analysis: Lateral ventricles volume analysis; comparator: vehicle-treated rats — Materials and methods > Drug administration (S64); Results > ChP CCL2 or CCR2 deficiencies effectively mitigate macrophage infiltration, reduce ChP inflammation, and ameliorate hydrocephalus in vivo (S218); Figure 7 legend (S318)
INCB 3284 1 mg/kg · Materials and methods > Drug administration (S64); Results > ChP CCL2 or CCR2 deficiencies effectively mitigate macrophage infiltration, reduce ChP inflammation, and ameliorate hydrocephalus in vivo (S218)
Fluid resuscitation requirements after hemorrhagic shock
Animal study · Male Sprague-Dawley rats (300–405 g); n = 6 [3]
In male Sprague-Dawley rats, a single dose of INCB 3284 administered through the left femoral artery transiently reduced fluid resuscitation requirements after hemorrhagic shock compared with vehicle-treated animals.
Conditions shared by the study groups
- Route
- left femoral artery
- Treatment course
- at t = 60 min
- Vehicle
- 1mL NS
- INCB 3284 5 μmol/kg
- Model: Male Sprague-Dawley rats (300–405 g); n = 6
Methods and source locations
Compound reported in the paper: INCB 3284
The paper names INCB 3284 without stating the salt or form; not verified as the dimesylate form supplied as A11104. No dose conversion or lot validation.
Materials and methods > Hemorrhagic shock models (S4, S9, S18, S20, S21); Fig 2 legend (S46, S50, S52)
Fluid resuscitation in mL/kg required to maintain MAP of 60 mmHg or systolic blood pressure (SBP) of 90 mmHg.: Fluid resuscitation in mL/kg required to maintain MAP of 60 mmHg or systolic blood pressure (SBP) of 90 mmHg.; comparator: 1 mL of normal saline (NS) (n = 6) — Fig 2 legend (S46, S52)
INCB 3284 5 μmol/kg · Materials and methods > Hemorrhagic shock models (S9, S21); Fig 2 legend (S46)
Reduced Serum ALT Levels in Acute Liver Failure
Animal study · male C57Bl/6 mice; Acute liver failure [1]
In male mice with acute liver failure, intraperitoneal INCB pretreatment before AOM significantly reduced serum ALT levels compared with AOM-treated mice alone.
Conditions shared by the study groups
- Route
- ip
- Treatment course
- for 3 days prior to injection of AOM
- INCB 3284 dimesylate 1 mg/kg/day
- Model: male C57Bl/6 mice; Acute liver failure
- Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations
Compound reported in the paper: INCB 3284 dimesylate; Compound label in the paper: INCB 3284
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Methods > Materials (S5); Methods > Mouse model of hepatic encephalopathy (S7, S9, S10, S12); Results > Inhibition of CCR2 or CCR4 is protective from AOM-induced neurological decline (S71); Figure 3 legend (S97, S98, S100, S104)
Serum ALT levels: Serum ALT levels; comparator: AOM-treated mice alone — Methods > Mouse model of hepatic encephalopathy (S10); Results > Inhibition of CCR2 or CCR4 is protective from AOM-induced neurological decline (S71); Figure 3 legend (S100, S104)
INCB 3284 dimesylate 1 mg/kg/day · Methods > Mouse model of hepatic encephalopathy (S10); Results > Inhibition of CCR2 or CCR4 is protective from AOM-induced neurological decline (S71); Figure 3 legend (S104)